Arbutus Biopharma (ABUS) Net Cash Flow (2013 - 2026)

Arbutus Biopharma has disclosed Net Cash Flow across 14 years of filings, most recently posting $5.7 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $5.7 million, up 669.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$13.4 million (down 123.09% YoY), and the FY2025 annual result was -$18.3 million, down 281.65% from the prior year.
• Net Cash Flow came in at $5.7 million for Q1 2026 at Arbutus Biopharma, up from -$4.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $19.7 million in Q2 2024 to a low of -$34.0 million in Q2 2022.
• The 5-year median for Net Cash Flow is $315000.0 (2025), against an average of -$5.0 million.
• Across the five-year window, Net Cash Flow sank 219.9% in 2024 and jumped 669.27% in 2026, its largest moves.
• Arbutus Biopharma's Net Cash Flow stood at $6.8 million in 2022, then climbed by 28.98% to $8.7 million in 2023, then slumped by 48.32% to $4.5 million in 2024, then sank by 197.43% to -$4.4 million in 2025, then soared by 229.7% to $5.7 million in 2026.
• The last three Net Cash Flow figures came in at $5.7 million (Q1 2026), -$4.4 million (Q4 2025), and -$15.0 million (Q3 2025), per Business Quant data.